cgp 42112a has been researched along with Cardiovascular Stroke in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, H; Hu, X; Jiang, Z; Li, J; Liu, X; Steinhoff, G; Wang, L; Xu, Y; Yu, H; Zhang, Z | 1 |
| Kim, MP; Wahl, LM; Zhou, M | 1 |
2 other study(ies) available for cgp 42112a and Cardiovascular Stroke
| Article | Year |
|---|---|
Preconditioning via angiotensin type 2 receptor activation improves therapeutic efficacy of bone marrow mononuclear cells for cardiac repair.
Topics: Angiotensin II; Animals; Apoptosis; Bone Marrow Cells; Cell Transplantation; Coculture Techniques; Echocardiography; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Inflammation; Leukocytes, Mononuclear; Male; Myocardial Infarction; Myocytes, Cardiac; Neovascularization, Physiologic; Nitric Oxide; Nitric Oxide Synthase Type III; Oligopeptides; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Stem Cell Transplantation; Tetrazoles; Valine; Valsartan; Vascular Endothelial Growth Factor A | 2013 |
Angiotensin II increases human monocyte matrix metalloproteinase-1 through the AT2 receptor and prostaglandin E2: implications for atherosclerotic plaque rupture.
Topics: Angiotensin II; Angiotensin II Type 2 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents; Cells, Cultured; Coronary Artery Disease; Dinoprostone; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Hypertension; Imidazoles; Matrix Metalloproteinase 1; Monocytes; Myocardial Infarction; Oligopeptides; Phosphoprotein Phosphatases; Pyridines; Receptor, Angiotensin, Type 2; Time Factors; Tumor Necrosis Factor-alpha; Up-Regulation | 2005 |